Relmada Therapeutics, Inc. filed a current report on November 12, 2026, announcing preliminary and unaudited financial results for the third fiscal quarter ended September 30, 2026, along with an updated corporate presentation.

Key Highlights

  • Reporting period: Preliminary, unaudited financial results cover the third fiscal quarter ended September 30, 2026.
  • Conference call: Relmada scheduled a call and audio webcast on November 12, 2026, at 4:30 PM EST / 1:30 PM PST to discuss results.
  • Exhibits furnished: A press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2) were furnished with the filing.
  • Not "filed" for Exchange Act purposes: The financial information is furnished under General Instruction B.2 and is not deemed "filed" under Section 18 of the Exchange Act.
  • Signed by CEO: Chief Executive Officer Sergio Traversa executed the filing on behalf of the registrant.

Relmada's Third-Quarter 2026 Corporate Update and Financial Disclosure

Relmada Therapeutics, Inc. (NASDAQ:RLMD), a Nevada-incorporated clinical-stage company headquartered at 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL, issued a press release on November 12, 2026, providing a corporate update along with preliminary and unaudited financial results for the three months ended September 30, 2026, according to the filing. The company noted that complete unaudited financial statements and accompanying notes, covering both the three and nine months ended September 30, 2026 and 2025, will be contained in its forthcoming Quarterly Report to be filed with the Securities and Exchange Commission.

In addition to the financial results, the filing disclosed that Relmada updated its corporate presentation on the same date, furnishing that document as Exhibit 99.2 under Item 7.01 Regulation FD Disclosure. Both the press release and the corporate presentation are described in the filing as "furnished" rather than "filed," meaning they are not deemed incorporated by reference into filings under the Securities Act of 1933 or the Exchange Act except where expressly specified. The filing was signed by Chief Executive Officer Sergio Traversa on behalf of Relmada Therapeutics, Inc.

What Was Disclosed

Relmada Therapeutics furnished a current report on November 12, 2026, covering preliminary Q3 2026 financial results and an updated corporate presentation, both described as not "filed" for Exchange Act Section 18 purposes. A conference call was held the same day at 4:30 PM EST.